Philadelphia chromosome-positive acute lymphoblastic leukemia

Yuichi Kodama, Hiroyuki Shimada

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

In the treatment of childhood Ph+ALL, TKI-combined chemotherapy has become the standard option, and HSCT in first remission is no longer an absolute indication. However, pediatric Ph+ALL is still a refractory leukemia, and 5-year EFS in children without HSCT in first remission was only 55-60% because of treatment-related death and post-chemotherapy relapse. Further improvement in clinical outcomes may require intensified targeted therapy in combination with low-intensity chemotherapy and/or immune antibody therapy with reduced toxicity. Continuing to address these challenges in prospective clinical studies will change childhood Ph+ALL from refractory leukemia to more manageable leukemia in the future.

Original languageEnglish
Title of host publicationPediatric Acute Lymphoblastic Leukemia
PublisherSpringer Singapore
Pages93-99
Number of pages7
ISBN (Electronic)9789811505485
ISBN (Print)9789811505478
DOIs
Publication statusPublished - 2019 Jan 1

Keywords

  • Bcr-abl1
  • Dasatinib
  • Philadelphia chromosome
  • Ponatinib
  • Tyrosine kinase inhibitor imatinib

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Philadelphia chromosome-positive acute lymphoblastic leukemia'. Together they form a unique fingerprint.

  • Cite this

    Kodama, Y., & Shimada, H. (2019). Philadelphia chromosome-positive acute lymphoblastic leukemia. In Pediatric Acute Lymphoblastic Leukemia (pp. 93-99). Springer Singapore. https://doi.org/10.1007/978-981-15-0548-5_10